Pediatric fibrolamellar hepatocellular carcinoma: case report and review of the literature

References

• Muthuvel E, Chander V, Srinivasan C. A clinicopathological study of paediatric liver tumours in a tertiary care hospital. J Clin Diagn Res. 2017;11(3):EC50–EC53.
   PubMed Web of Science ®Google Scholar
• Chiorean L, Cui XW, Tannapfel A, et al. Benign liver tumors in pediatric patients – review with emphasis on imaging features. World J Gastroenterol. 2015;21(28):8541–8561.
   PubMed Web of Science ®Google Scholar
• Kassahun WT. Contemporary management of fibrolamellar hepatocellular carcinoma: diagnosis, treatment, outcome, prognostic factors, and recent developments. World J Surg Oncol. 2016;14(1):151.
   PubMedGoogle Scholar
• Chagas AL, Kikuchi L, Herman P, et al. Clinical and pathological evaluation of fibrolamellar hepatocellular carcinoma: a single center study of 21 cases. Clinics. 2015;70(3):207–213.
   PubMed Web of Science ®Google Scholar
• Lim II, Farber BA, LaQuaglia MP. Advances in fibrolamellar hepatocellular carcinoma: a review. Eur J Pediatr Surg. 2014;24(6):461–466.
   PubMed Web of Science ®Google Scholar
• Lalazar G, Simon SM. Fibrolamellar carcinoma: recent advances and unresolved questions on the molecular mechanisms. Semin Liver Dis. 2018;38(1):51–59.
   PubMed Web of Science ®Google Scholar
• Darcy DG, Malek MM, Kobos R, et al. Prognostic factors in fibrolamellar hepatocellular carcinoma in young people. J Pediatr Surg. 2015;50(1):153–156.
   PubMed Web of Science ®Google Scholar
• Schmid I, von Schweinitz D. Pediatric hepatocellular carcinoma: challenges and solutions. J Hepatocell Carcinoma. 2017;4(8):51–21.
   Google Scholar
• Walther A, Tiao G. Approach to pediatric hepatocellular carcinoma. Clin Liver Dis. 2013;2(5):219–222.
   Google Scholar
• Chaudhari VA, Khobragade K, Bhandare M, et al. Management of fibrolamellar hepatocellular carcinoma. Chin Clin Oncol. 2018;7(5):51.
   PubMed Web of Science ®Google Scholar
• Smith MT, Blatt ER, Jedlicka P, et al. Fibrolamellar hepatocellular carcinoma. Radiographics. 2008;28(2):609.
   PubMed Web of Science ®Google Scholar
• Sergi CM. Hepatocellular carcinoma, fibrolamellar variant: diagnostic pathologic criteria and molecular pathology update. A primer. Diagnostics (Basel). 2015;6(1):pii: E3.
   Google Scholar
• Zen Y, Vara R, Portmann B, et al. Childhood hepatocellular carcinoma: a clinicopathological study of 12 cases with special reference to EpCAM. Histopathology. 2014;64(5):671–682.
   PubMed Web of Science ®Google Scholar
• Riggle KM, Turnham R, Scott JD, et al. Fibrolamellar hepatocellular carcinoma: mechanistic distinction from adult hepatocellular carcinoma. Pediatr Blood Cancer. 2016;63(7):1163–1167.
   PubMed Web of Science ®Google Scholar
• Malouf GB, Le Deley M, Faivre S, et al. Pure and mixed fibrolamellar hepatocellular carcinomas differ in natural history and prognosis after complete surgical resection. Cancer. 2012;118(20):4981–4990.
   PubMed Web of Science ®Google Scholar
• Edmondson HA. Differential diagnosis of tumors and tumor-like lesions of liver in infancy and childhood. AMA Am J Dis Child. 1956;91(2):168–186.
   PubMedGoogle Scholar
• Weeda VB, Murawski M, McCabe AJ, et al. Fibrolamellar variant of hepatocellular carcinoma does not have a better survival than conventional hepatocellular carcinoma–results and treatment recommendations from the Childhood Liver Tumour Strategy Group (SIOPEL) experience. Eur J Cancer. 2013;49(12):2698–2704.
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Davila JA. Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study. Hepatology. 2004;39(3):798–803.
   PubMed Web of Science ®Google Scholar
• Ganeshan D, Szklaruk J, Kundra V, et al. Imaging features of fibrolamellar hepatocellular carcinoma. AJR Am J Roentgenol. 2014;202(3):544–552.
   PubMed Web of Science ®Google Scholar
• Epstein BP, Haulk T, Herpst J, et al. Metastatic nonresectable fibrolamellar hepatoma: prognostic features and natural history. Am J Clin Oncol. 1999;22(1):22–28.
   PubMed Web of Science ®Google Scholar
• McLarney JK, Rucker PT, Bender GN, et al. Fibrolamellar carcinoma of the liver: radiologic-pathologic correlation. Radiographics. 1999;19(2):453–471.
   PubMed Web of Science ®Google Scholar
• Liu S, Chan KW, Wang B, et al. Fibrolamellar hepatocellular carcinoma. Am J Gastroenterol. 2009;104(10):2617–2624.
   PubMed Web of Science ®Google Scholar
• Ehrenfried JA, Zhou Z, Thompson JC, et al. Expression of the neurotensin gene in fetal human liver and fibrolamellar carcinoma. Ann Surg. 1994;220(4):484–489.
   PubMed Web of Science ®Google Scholar
• Torbenson M. Fibrolamellar carcinoma: 2012 update. Scientifica (Cairo). 2012;2012:743790.
   PubMedGoogle Scholar
• Waxman S, Gilbert HS. A tumor-related vitamin B12 binding protein in adolescent hepatoma. N Engl J Med. 1973;289(20):1053–1056.
   PubMed Web of Science ®Google Scholar
• Lildballe DL, Nguyen KQT, Poulsen SS, et al. Haptocorrin as marker of disease progression in fibrolamellar hepatocellular carcinoma. Eur J Surg Oncol. 2011;37(1):72–79.
   PubMed Web of Science ®Google Scholar
• Squires RH, Ng V, Romero R, et al. Evaluation of the pediatric patient for liver transplantation: 2014 practice guideline by the American Association for the Study of Liver Diseases, American Society of Transplantation and the North American Society for Pediatric Gastroenterology. Hepatology and Nutrition. Hepatology. 2014;60(1):362–398.
   PubMed Web of Science ®Google Scholar
• Pinna AI, Lee R, Todo S, et al. Treatment of fibrolamellar hepatoma with subtotal hepatectomy or transplantation. Hepatology. 1997;26(4):877–883.
   PubMed Web of Science ®Google Scholar
• Maniaci V, Davidson BR, Rolles K, et al. Fibrolamellar hepatocellular carcinoma: prolonged survival with multimodality therapy. Eur J Surg Oncol. 2009;35(6):617–621.
   PubMed Web of Science ®Google Scholar
• Fonseca GM, Varella AD, Coelho FF, et al. Downstaging and resection after neoadjuvant therapy for fibrolamellar hepatocellular carcinoma. World J Gastrointest Surg. 2014;6(6):107.
   PubMedGoogle Scholar
• Gras P, Truant S, Boige V, et al. Prolonged complete response after GEMOX chemotherapy in a patient with advanced fibrolamellar hepatocellular carcinoma. Case Rep Oncol. 2012;5(1):169–172.
   PubMedGoogle Scholar
• Katzenstein HM, Krailo MD, Malogolowkin MH, et al. Fibrolamellar hepatocellular carcinoma in children and adolescents. Cancer. 2003;97(8):2006–2012.
   PubMed Web of Science ®Google Scholar
• Pham TH, Iqbal CW, Grams JM, et al. Outcomes of primary liver cancer in children: an appraisal of experience. J Pediatr Surg. 2007;42(5):834–839.
   PubMed Web of Science ®Google Scholar
• Atienza LB, Mei X, Shah MB, et al. Liver transplantation for fibrolamellar hepatocellular carcinoma: a national perspective. J Surg Oncol. 2017;115(3):319–323.
   PubMed Web of Science ®Google Scholar
• El-Gazzaz GWW, El-Hadary M, Gunson B, et al. Outcome of liver resection and transplantation for fibrolamellar hepatocellular carcinoma. Transpl Int. 2000;13(S1):S406–S409.
   PubMedGoogle Scholar
• Verslype C, Rosmorduc O, Rougier P, et al. Hepatocellular carcinoma: ESMO-ESDO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii41–8.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236.
   PubMed Web of Science ®Google Scholar